Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age

被引：0
|
作者：
Sartor, Oliver [1 ]
Coleman, Robert [2 ]
Nilsson, Sten [3 ]
Heinrich, Daniel [4 ]
Staudacher, Karin
Garcia-Vargas, Jose
Vogelzang, Nicholas [5 ]
机构：
[1] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
[2] Weston Pk Hosp, Sheffield, S Yorkshire, England
[3] Karolinska Univ Hosp, Stockholm, Sweden
[4] Akershus Univ Hosp, Nordbyhagen, Norway
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [41] Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Heinrich, D.
    Parker, C.
    Shan, M.
    Wilhelm, S.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Sartor, O.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 177 - 178
  • [42] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
    Sternberg, Cora N.
    Saad, Fred
    Graff, Julie Nicole
    Peer, Avivit
    Vaishampayan, Ulka N.
    Leung, Eugene
    Rosenbaum, Eli
    Gurney, Howard
    Epstein, Richard
    Davis, Ian D.
    Wu, Bingyan
    Trandafir, Lucia
    Wagner, Volker Jean
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
  • [44] Treatment Patterns, Patient Characteristics, and Preliminary Safety in the Radium-223 (Ra-223) REASSURE Observational Study
    Zimberg, S. H.
    Richardson, T.
    Sylvester, J. E.
    Given, R.
    Kipper, M.
    Mantz, C.
    Morris, D.
    Perlmutter, M.
    Song, D.
    Fernandez, E.
    Brookland, R. K.
    Tchekmedyian, N.
    Hafron, J.
    Hartford, A. C.
    Peddada, A. V.
    Vacirca, J.
    De Sanctis, Y.
    Muenz-Wollny, R.
    Conti, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E281 - E282
  • [45] 3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) Patients (Pts) With Symptomatic Bone Metastases (Mets) From ALSYMPCA
    Koenig, E.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Voyelzang, N.
    Staudacher, K.
    Thuresson, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 86 - 86
  • [46] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [47] 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N. J.
    Staudacher, K.
    Thuresson, M.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S477 - S477
  • [48] Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.
    Omlin, Aurelius Gabriel
    Daugaard, Gedske
    Peer, Avivit
    Reichegger, Hermann
    Neumann, Avivit
    Rosenbaum, Eli
    Desax, Marie-Claire
    Neiman, Victoria
    Petersen, Peter Meidahl
    Mueller, Joachim
    Cathomas, Richard
    Gottfried, Maya
    Sarid, David
    Gez, Eli
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Mortensen, Jann
    Gillessen, Silke
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
    Finkelstein, Steven E.
    Michalski, Jeff M.
    O'Sullivan, Joe M.
    Parker, Chris
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [50] Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study.
    Nilsson, Sten
    Tomblyn, Michael
    Cislo, Paul
    Reuning-Scherer, Jonathan
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345